OPK OPKO HEALTH, INC. Insider Trading

Director John A Paganelli bought 10,000 shares of OPK at $1.14 on 2026-03-20; stock down -39.8% from 52-week high.

Director Paganelli purchased 10,000 shares at $1.14, increasing his holdings to 394,340 shares. The transaction occurs as OPK trades 39.8% below its 52-week high of $1.86 and down 14.5% over the prior 90 days. Paganelli's own prior buy at OPK on 2024-01-05 delivered a 90-day return of +54.0%, suggesting his timing has been accurate at this ticker in the past. However, OPK's fundamentals present a complex backdrop: while the latest quarter showed $21.6M net income, the company was unprofitable over its most recent full fiscal year with annual revenue declining 14.9% year-over-year, and the current market cap stands at $850.2M against a depressed share price.

CEO Frost buys 580,000 OPK shares across 5 transactions (Nov 21) at $1.30–$1.34, averaging $1.33

CEO & Chairman Phillip Frost executed 5 separate purchases totaling 580,000 shares for $768,807.41 on 2025-11-21, with per-transaction prices ranging from $1.30 to $1.34. This acquisition occurs as the stock is -32.0% from its 52-week high and -12.6% down over the past 30 days, bringing his holdings to 216.71M shares. While Frost has a cross-ticker track record of 20 prior open-market buys, his same-ticker history at OPK shows 5 recent buys on 2025-11-20 whose outcomes are not yet measurable. The company's latest quarter shows revenue of $151.7M and net income of $21.6M, but full-year results were negative and annual revenue contracted -17.4%. The large share count added (0.3% of pre-transaction holdings) paired with depressed price conditions and deteriorating fundamentals warrants attention to whether this reflects conviction or follows an established pattern of trading activity at this level.

CEO/Chairman Frost purchases 580,000 OPK shares across 7 transactions for $771,327.71 on 2025-11-20

FROST PHILLIP MD ET AL, CEO and Chairman of OPKO HEALTH, INC., executed 7 separate purchases totaling 580,000 shares on 2025-11-20 at a blended average price of $1.33, spending $771,327.71 and increasing holdings to 216,126,448 shares. The transaction occurred against a backdrop of significant negative price momentum: the stock trades at $1.30, down 33.0% from its 52-week high of $1.94, with a 30-day decline of -12.2%. The company faces substantial headwinds, with annual revenue declining 17.4% year-over-year and net income turning negative over the most recent full fiscal year, though the latest quarterly results showed $151.7M in revenue and $21.6M in net income. The CEO's purchases on 2025-11-20 followed prior acquisitions on 2025-11-19, suggesting consecutive days of active accumulation. His cross-ticker track record includes 20 prior buys, but timing outcomes at OPK specifically remain unmeasurable given the very recent entry dates.

CEO Phillip Frost buys 580,000 shares across 9 transactions for $759,115.41 on 2025-11-19

On 2025-11-19, CEO & Chairman Phillip Frost executed 9 separate purchases totaling 580,000 shares at an average of $1.31, increasing his holdings from 214.97M to 215.55M shares (+0.3%). The stock has declined 32.5% from its 52-week high of $1.94 and dropped 14.4% over the prior 30 days, trading at the lower end of its range. However, this purchase comes one day after five consecutive buy transactions on 2025-11-18, suggesting a sustained accumulation pattern rather than a opportunistic single-day decision. Frost's cross-ticker track record shows modest performance: 20 prior buys with an average 30-day return of -2.0% and 90-day return of -6.5%, with a 37.5% win rate at the 90-day horizon. At OPK specifically, all five prior trades executed yesterday remain unmeasurable. The company is unprofitable on a full-year basis and revenue contracted 17.4% year-over-year, adding fundamental headwinds to the technical weakness.

Frost buys 533,300 shares at blended $1.27 for $678.9K as OPK stock down -34.0% from 52-week high

Frost Phillip MD, CEO & Chairman, executed 11 separate purchases totaling 533,300 shares for $678,905.84 on 2025-11-18 at prices ranging from $1.24 to $1.29, establishing a blended average purchase price of $1.27. The current stock price of $1.28 reflects a -34.0% decline from the 52-week high of $1.94 and a -15.8% drop over the past 30 days. Frost's same-ticker trading history at OPK shows mixed outcomes: of 4 completed trades, 2 achieved positive 90-day returns (August buy +4.6%, April buy +1.6%) while 2 resulted in losses (April buy -9.3%, April buy -19.9%), suggesting a 50% accuracy rate at this ticker. The company faces headwinds with annual revenue declining -17.4% and a negative full-year net income, though the most recent quarter posted $21.6M in net income against $151.7M in revenue. This acquisition adds 533,300 shares to his substantial 214.97M share post-transaction position, a +0.2% increase in his holdings.

CEO Frost buys 150,000 OPK shares at $1.42; stock now $1.36. Prior 4 of 5 same-ticker buys posted losses at 90 days.

FROST PHILLIP MD ET AL, CEO & Chairman, purchased 150,000 shares of OPKO HEALTH at $1.42 on 2025-10-31, adding to a post-transaction holding of 214.39M shares. The buy occurred as the stock trades at $1.36, down 12.3% over 30 days and 29.9% below its 52-week high of $1.94. Examining his five prior open-market purchases at OPK reveals a concerning pattern: four of the five resulted in negative 90-day returns, ranging from -9.3% to -22.2%, with only one prior buy (2025-08-08) showing a 90-day gain of 2.3%. His cross-ticker track record of 20 buys shows a 57.89% 90-day win rate and average 90-day return of +2.9%, but his ticker-specific outcomes at OPK have underperformed that benchmark significantly. The company reported annual revenue growth of -17.4% and was unprofitable on a full-year basis, setting a contrasting backdrop against the CEO's continued accumulation despite repeated post-purchase declines in prior transactions at this ticker.

CEO Frost bought 675.0K shares of OPK at $1.32, expanding holdings to 214.68M; prior 5 same-ticker buys underperformed vs. cross-ticker record.

Phillip Frost (CEO & Chairman) purchased 675,000 shares for $891,000.00 at $1.32, now holding 214.68M shares post-transaction. His cross-ticker track record shows 20 prior buys with an average 90-day return of +3.2% (57.89% win rate), but his same-ticker history at OPK is notably weaker: 5 prior buys, only 1 of which posted a positive 90-day return, with the most recent four trades showing 90-day losses ranging from -9.3% to -23.5%. The stock trades at -35.6% from its 52-week high of $1.94, down 9.4% over 30 days. Fundamentals reveal the company is unprofitable with a full-year net loss of $-148.4M, revenue contraction of -17.4% year-over-year, and a market cap of $992.2M. This buy occurs against a backdrop of consistent underperformance in prior same-ticker acquisitions and deteriorating financial metrics, with no recent well-timed entries at this ticker to offset the pattern.

CEO Phillip Frost buys 125,000 OPK shares at $1.36; stock down 29.9% from 52-week high, amid revenue decline and negative annual results.

On 2025-04-10, Phillip Frost, CEO & Chairman, purchased 125,000 shares of OPKO HEALTH at $1.36, adding to his already substantial 213.88M share holdings. The purchase occurs as OPK trades -29.9% from its 52-week high and -24.4% over 30 days, following a full-year period of -17.4% annual revenue decline and negative net income. Frost's cross-ticker track record shows 20 prior buys averaging +7.5% return in 30 days and +21.2% in 90 days with 100% win rate, but at OPK specifically he has executed 5 buys in the past month (2025-02-28 through 2025-04-10) with only the Feb 28 trade having a 30-day measurement (-0.6%). The rapid succession of purchases at a depressed price level warrants attention to whether operational fundamentals are stabilizing or whether market perception has decoupled from intrinsic value; the absence of measurable positive returns on prior same-ticker trades limits confidence that this pattern reflects conviction-backed timing accuracy specific to OPKO.

CEO Frost buys 125,000 OPK shares at $1.48 amid -23.2% 30-day decline; fourth purchase in 11 days

OPKO's CEO purchased 125,000 shares at $1.48 on 2025-04-08, the fourth distinct buy transaction within an 11-day window (following purchases on 2025-01-28, 2025-02-28, 2025-03-17, 2025-03-28, and 2025-04-01). This represents a sustained accumulation pattern while the stock declined 23.2% over 30 days and 24.7% from its 52-week high of $1.94. The company's fundamentals show recent weakness: full-year net income was negative, annual revenue contracted 17.4%, yet the latest quarter reported $173.6M revenue and $24.9M net income. The CEO's cross-ticker track record demonstrates a 100% 90-day win rate with average +22.6% returns across 20 prior open-market buys, though at OPK specifically, prior same-ticker outcomes remain mostly unmeasured or negative (one trade at +10.6% 30-day, one at -0.6%). The timing pattern of recent rapid-fire purchases during sharp price decline warrants tracking against forward results to establish whether this constitutes predictive accumulation or reflects other operational context.

OPKO CEO Frost buys 100,000 shares at $1.65; 5 acquisitions in 2 weeks amid -17.4% annual revenue decline

FROST PHILLIP MD ET AL, CEO & Chairman, purchased 100,000 shares at $1.65 on 2025-04-01, the latest in a series of five open-market acquisitions at OPK within 14 days (2025-03-17 through 2025-04-01), totaling accumulation during a period when annual revenue growth was -17.4% and the company was unprofitable over its most recent full fiscal year. The stock currently trades at $1.66, down 4.6% over 30 days and 14.4% from its 52-week high of $1.94, suggesting the purchases occurred as the stock faced downward pressure. Across his prior five same-ticker transactions, the CEO's most measurable trade (2025-01-28 buy) showed a 30-day gain of +10.6%, while his cross-ticker track record demonstrates a 100% win rate at the 90-day horizon, though no prior same-ticker purchases have yet completed a 90-day measurement window. The intensity and timing of the recent accumulation—particularly buying within a narrow timeframe—warrants attention given the company's deteriorating fundamentals, though the outcome depends on whether operational trends stabilize.